Homo- and heterodimeric SMAC mimetic compounds as apoptosis inducers
US-9321808-B2 · Apr 26, 2016 · US
Romidepsin solid forms and uses thereof
US9518094B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9518094-B2 |
| Application number | US-201514615384-A |
| Country | US |
| Kind code | B2 |
| Filing date | Feb 5, 2015 |
| Priority date | Jul 12, 2010 |
| Publication date | Dec 13, 2016 |
| Grant date | Dec 13, 2016 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present disclosure provides solid forms of a compound of formula I. In some embodiments, the present disclosure provides crystalline forms of Compound I. In some embodiments, the present disclosure provides solvate forms of Compound I. In some embodiments, the present disclosure provides amorphous Compound I.
First claim
Opening claim text (preview).
The invention claimed is: 1. A crystalline form of romidepsin characterized by: XRPD characteristic peaks at about 9.0 2θ, 10.3 2θ, 11.7 2θ, and 20.4 2θ; a differential scanning calorimetry (DSC) thermogram having endotherm at ˜255° C.; or a thermogravimetric analysis (TGA) thermogram exhibiting a weight loss of ˜10.9%. 2. A pharmaceutical composition comprising the crystalline form of romidepsin of claim 1 and a pharmaceutically acceptable excipient. 3. A method of treating a hematological disorder comprising administering to a subject the crystalline form of romidepsin of claim 1 , wherein the hematological disorder is cutaneous T-cell lymphoma (CTCL) or peripheral T-cell lymphoma (PTCL). 4. The method of claim 3 , wherein the hematological disorder is cutaneous T-cell lymphoma (CTCL). 5. The method of claim 3 , wherein the hematological disorder is peripheral T-cell lymphoma (PTCL). 6. A method of treating a hematological disorder comprising administering to a subject the pharmaceutical composition of claim 2 , wherein the hematological disorder is cutaneous T-cell lymphoma (CTCL) or peripheral T-cell lymphoma (PTCL).
Assignees
Inventors
Classifications
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9518094B2 cover?
- The present disclosure provides solid forms of a compound of formula I. In some embodiments, the present disclosure provides crystalline forms of Compound I. In some embodiments, the present disclosure provides solvate forms of Compound I. In some embodiments, the present disclosure provides amorphous Compound I.
- Who is the assignee on this patent?
- Celgene Corp
- What technology area does this patent fall under?
- Primary CPC classification C07K5/101. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Dec 13 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).